{"id":"https://openalex.org/W7127080047","doi":"https://doi.org/10.1007/s12020-025-04541-z","title":"Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells","display_name":"Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells","publication_year":2026,"publication_date":"2026-02-03","ids":{"openalex":"https://openalex.org/W7127080047","doi":"https://doi.org/10.1007/s12020-025-04541-z","pmid":"https://pubmed.ncbi.nlm.nih.gov/41629585"},"language":"en","primary_location":{"id":"doi:10.1007/s12020-025-04541-z","doi":"https://doi.org/10.1007/s12020-025-04541-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s12020-025-04541-z","pdf_url":null,"source":{"id":"https://openalex.org/S194842327","display_name":"Endocrine","issn_l":"0969-711X","issn":["0969-711X","1355-008X","1559-0100"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7127080047"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101810693","display_name":"Ricardo Rodrigues","orcid":"https://orcid.org/0000-0003-1928-4106","observed_orcids":["https://orcid.org/0000-0003-1928-4106"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]},{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Ricardo Rodrigues","raw_affiliation_strings":["NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa, Lisboa, Portugal","Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal"],"raw_orcid":"https://orcid.org/0000-0003-1928-4106","affiliations":[{"raw_affiliation_string":"NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]},{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013892331","display_name":"Carolina Pires","orcid":"https://orcid.org/0000-0001-5820-5269","observed_orcids":["https://orcid.org/0000-0001-5820-5269"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]},{"id":"https://openalex.org/I83558840","display_name":"Universidade Nova de Lisboa","ror":"https://ror.org/02xankh89","country_code":"PT","type":"education","lineage":["https://openalex.org/I83558840"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Carolina Pires","raw_affiliation_strings":["NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa, Lisboa, Portugal","Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NOVA Medical School, Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa, Lisboa, Portugal","institution_ids":["https://openalex.org/I83558840"]},{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054149298","display_name":"Carmo Martins","orcid":"https://orcid.org/0000-0002-7901-7600","observed_orcids":["https://orcid.org/0000-0002-7901-7600"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Carmo Martins","raw_affiliation_strings":["Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024166264","display_name":"Valeriano Alberto Pais Horta Leite","orcid":"https://orcid.org/0000-0001-5479-7332","observed_orcids":["https://orcid.org/0000-0001-5479-7332"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Valeriano Leite","raw_affiliation_strings":["Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]},{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5124778340","display_name":"Tiago Nunes da Silva","orcid":"https://orcid.org/0000-0002-1958-4531","observed_orcids":["https://orcid.org/0000-0002-1958-4531"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Tiago Nunes da Silva","raw_affiliation_strings":["Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]},{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal","institution_ids":["https://openalex.org/I4210103180"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065364190","display_name":"Branca Maria Cavaco","orcid":"https://orcid.org/0000-0001-8946-8635","observed_orcids":["https://orcid.org/0000-0001-8946-8635"]},"institutions":[{"id":"https://openalex.org/I4210103180","display_name":"Instituto Portugu\u00eas de Oncologia Francisco Gentil","ror":"https://ror.org/00r7b5b77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210103180"]}],"countries":["PT"],"is_corresponding":true,"raw_author_name":"Branca Maria Cavaco","raw_affiliation_strings":["Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal. bcavaco@ipolisboa.min-saude.pt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal. bcavaco@ipolisboa.min-saude.pt","institution_ids":["https://openalex.org/I4210103180"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5065364190"],"corresponding_institution_ids":["https://openalex.org/I4210103180"],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"91","issue":"1","first_page":"59","last_page":"59"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11728","display_name":"Thyroid and Parathyroid Surgery","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":0.968999981880188},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.9139999747276306},{"id":"https://openalex.org/keywords/papillary-thyroid-carcinoma","display_name":"papillary thyroid carcinoma","score":0.8920000195503235},{"id":"https://openalex.org/keywords/lenvatinib-resistance","display_name":"lenvatinib resistance","score":0.7910000085830688},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.8169999718666077},{"id":"https://openalex.org/keywords/ret-ptc1","display_name":"RET/PTC1","score":0.9879999756813049},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.9800000190734863},{"id":"https://openalex.org/keywords/adaptive-resistance","display_name":"adaptive resistance","score":0.7250000238418579}],"concepts":[{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.9318000078201294},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.8934999704360962},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6552000045776367},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6126999855041504},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.5911999940872192},{"id":"https://openalex.org/C2781209748","wikidata":"https://www.wikidata.org/wiki/Q419953","display_name":"Topotecan","level":3,"score":0.5493000149726868},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.5156999826431274},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.5145999789237976},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.444599986076355},{"id":"https://openalex.org/C2781461381","wikidata":"https://www.wikidata.org/wiki/Q2292945","display_name":"Papillary thyroid cancer","level":4,"score":0.44429999589920044},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.4271000027656555},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.41519999504089355},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.4036000072956085},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.3788999915122986},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3637000024318695},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36169999837875366},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.3499999940395355},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.3163999915122986},{"id":"https://openalex.org/C2993294228","wikidata":"https://www.wikidata.org/wiki/Q13632630","display_name":"Thyroid carcinoma","level":3,"score":0.3138999938964844},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.304500013589859},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.2921000123023987},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.2919999957084656},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2791000008583069},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.265500009059906},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.25609999895095825}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013964","descriptor_name":"Thyroid Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1007/s12020-025-04541-z","doi":"https://doi.org/10.1007/s12020-025-04541-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s12020-025-04541-z","pdf_url":null,"source":{"id":"https://openalex.org/S194842327","display_name":"Endocrine","issn_l":"0969-711X","issn":["0969-711X","1355-008X","1559-0100"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine","raw_type":"journal-article"},{"id":"pmid:41629585","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41629585","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320334779","display_name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","ror":"https://ror.org/00snfqn58"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":46,"referenced_works":["https://openalex.org/W1848939527","https://openalex.org/W1967792499","https://openalex.org/W2019294726","https://openalex.org/W2024570610","https://openalex.org/W2040316588","https://openalex.org/W2040642592","https://openalex.org/W2054020870","https://openalex.org/W2062871120","https://openalex.org/W2085794439","https://openalex.org/W2091494856","https://openalex.org/W2094109552","https://openalex.org/W2145150141","https://openalex.org/W2155696445","https://openalex.org/W2270997383","https://openalex.org/W2279570938","https://openalex.org/W2291457300","https://openalex.org/W2504980652","https://openalex.org/W2791811230","https://openalex.org/W2913765486","https://openalex.org/W2938150871","https://openalex.org/W2967737927","https://openalex.org/W2974496240","https://openalex.org/W2988896392","https://openalex.org/W2997989649","https://openalex.org/W3005662902","https://openalex.org/W3014482292","https://openalex.org/W3110301740","https://openalex.org/W3135644338","https://openalex.org/W3137149901","https://openalex.org/W3167959356","https://openalex.org/W3183709015","https://openalex.org/W4225158169","https://openalex.org/W4226145353","https://openalex.org/W4229008260","https://openalex.org/W4283167856","https://openalex.org/W4285493516","https://openalex.org/W4292261975","https://openalex.org/W4294071838","https://openalex.org/W4294785826","https://openalex.org/W4320495561","https://openalex.org/W4384070626","https://openalex.org/W4388194957","https://openalex.org/W4389303027","https://openalex.org/W4393035962","https://openalex.org/W4399992181","https://openalex.org/W4412751500"],"related_works":["https://openalex.org/W4283167856","https://openalex.org/W7144837600","https://openalex.org/W7159963566","https://openalex.org/W2153391221","https://openalex.org/W3207451600","https://openalex.org/W2507146567","https://openalex.org/W2346159064","https://openalex.org/W2460215858","https://openalex.org/W3012120128"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2026-02-03T00:00:00"}